Renal and bone side effects of Entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate in patients with hepatitis B: a network meta- analysis

Author:

Liu Zekun1,Zhao Zhenzhen1,Ma Xuefeng1,Liu Shousheng1,Xin Yongning1

Affiliation:

1. Qingdao Municipal Hospital Affiliated to Qingdao University

Abstract

Abstract Background As the first-line treatment for chronic hepatitis B virus infection, the long-term effects of nucleoside analogues on kidney and bone tissue damage need to be further investigated. Methods Two investigators independently searched for relevant randomized controlled trials. We included all randomized controlled trials of nucleoside analogues in the treatment of patients with chronic hepatitis B through November 2021. A random effects model was constructed on our data using stata15 software, and the standardized mean difference (SMD) and 95% confidence interval (95% CI) and surface under the cumulative ranking (SUCRA) were reported for each outcome. The side effects of the three drugs were compared. Results This study eventually included 17 studies involving 4278 adults with chronic hepatitis B. Entecavir (ETV) and tenofovir alafenamide (TAF) had less effect on estimated glomerular filtration rate (eGFR) than tenofovir disoproxil fumarate (TDF) (SMD= 3.60, 95%Cl: 1.94~5.26) and (SMD=4.27, 95%Cl :2.62~5.93). ETV had less effect on creatinine rise than TAF and TDF, SMD=0.55(95%Cl:0.09~1.01), SMD=0.61(95% Cl:0.15~1.06). The effect of TAF on bone mineral density(BMD) was less than that of TDF, with SMD=0.02 (95%Cl: 0.01~0.02). The probability of three drugs reducing relevant indicators is, eGFR: TDF(100.0%)>ETV(41.2%)>TAF(8.8%); BMD:TDF (79.7%)>ETV (50.6%)>TAF(19.6%); blood phosphorus: TDF (90.6%)>TAF(49.8%)>ETV(9.7%). The probability of three drugs to increase creatinine in the order: TDF (94.7%)>TAF (54.7%) >ETV (0.6%). Conclusions TDF has shown stronger side effects than TAF and ETV in both renal function and bone tissue.

Publisher

Research Square Platform LLC

Reference33 articles.

1. Tu T, Douglas MW. Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses, 2020. 12(12).

2. A global scientific strategy to cure hepatitis B. The Lancet;Revill PA;Gastroenterol Hepatol,2019

3. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives;Sun D;Eur J Med Chem,2018

4. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017. 67(2): p. 370–98.

5. Hepatitis B virus infection;Yuen M-F;Nat Reviews Disease Primers,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3